Confirmed graft flow following use of recombinant factor VIIa in coronary artery bypass grafting: a case report and literature review.
We present our experience of a unique opportunity to survey coronary artery bypass graft (CABG) patency following the administration of recombinant factor VIIa in the early postoperative period. A review of the published literature on use of this medication in cardiothoracic surgery, specifically CABG, is included.
Beldowicz
Brian C
BC
Department of Cardiothoracic Surgery, Madigan Army Medical Center, Tacoma, WA 98431-1100, USA.
McDonald
Jerome M
JM
Needham
C Scott
CS
D000368:Aged; D001777:Blood Coagulation / Q000187:drug effects; D002315:Cardiopulmonary Bypass; D003131:Combined Modality Therapy; D001026:Coronary Artery Bypass; D003326:Coronary Circulation / Q000187:drug effects*; D003327:Coronary Disease / Q000097:blood / Q000503:physiopathology / Q000601:surgery; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D005260:Female; D006801:Humans; D007423:Intra-Aortic Balloon Pumping; D011994:Recombinant Proteins / Q000627:therapeutic use; D012501:Saphenous Vein / Q000637:transplantation; D014654:Vascular Patency / Q000187:drug effects
D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa